PDCD1 and metastatic colorectal cancer: Antibodies against programmed cell death 1 or its ligand (PD-1/L1 inhibitors), such as pembrolizumab and nivolumab, has proven to be a viable treatment option for patients with metastatic colorectal cancer who have high microsatellite instability or deficient mismatch repair.